Recent trial evidence and the 2018 cholesterol guidelines have reshaped lipid management. As clinicians are still learning how to incorporate the established nonstatins into the treatment of high-risk patients, two novel nonstatin agents (bempedoic acid and inclisiran) may again change the approach to lipid management.

Throughout this course, you’ll have the chance to explore the current lipids landscape and learn about the latest developments in cholesterol management.

Certified Patient Cases

Apply your knowledge of nonstatin therapies in management of ASCVD patients according to the latest guidelines and trial data.

 
   
Self-Paced Learning

Jump into this engaging eLearning curriculum to navigate the evolving lipids landscape with the current role of nonstatin therapies and explore the newest additions to the armamentarium of lipid lowering therapies.

 




  
Webinar

Join expert faculty Kim Birtcher, PharmD, AACC, Christie M. Ballantyne, MD, FACC, and Anne C. Goldberg, MD as they review the latest trial results, novel mechanisms of action, and anticipated clinical implications of the newest lipid lowering therapies.

 


  
Click here to see additional Spotlight Topics in the Clinical Spotlight Series

We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection:

Kim K. Birtcher, PharmD, AACC

Christie M. Ballantyne, MD, FACC

Anne C. Goldberg, MD

Aliza Hussain, MD – (certified patient case author, not involved in the webinar)

Supported by: Esperion Therapeutics, Inc. and The Medicines Company, a Novartis Company
Powered By